For this reason, multiple phase 1/2 trials were focused on modulating IDO (the first and rate-limiting step of the catabolic tryptophan-kynurenine pathway frequently overexpressed in GBM) through small molecule inhibitors to improve the patient response to immune checkpoint inhibitors, such as anti-PD-1 and anti-PD-L1 therapy. This evidence concerns the gene IDO1 and glioblastoma.